Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON vs CADILA HEALTHCARE - Comparison Results

BIOCON      Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

CADILA HEALTHCARE 
   Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    BIOCON CADILA HEALTHCARE BIOCON /
CADILA HEALTHCARE
 
P/E (TTM) x 34.9 29.4 118.7% View Chart
P/BV x 4.4 4.7 93.3% View Chart
Dividend Yield % 0.2 0.7 30.5%  

Financials

 BIOCON    CADILA HEALTHCARE
EQUITY SHARE DATA
    BIOCON
Mar-19
CADILA HEALTHCARE
Mar-20
BIOCON /
CADILA HEALTHCARE
5-Yr Chart
Click to enlarge
High Rs707352 200.8%   
Low Rs554207 268.2%   
Sales per share (Unadj.) Rs91.9139.2 66.0%  
Earnings per share (Unadj.) Rs16.711.8 142.0%  
Cash flow per share (Unadj.) Rs24.218.6 130.2%  
Dividends per share (Unadj.) Rs1.003.50 28.6%  
Dividend yield (eoy) %0.21.3 12.7%  
Book value per share (Unadj.) Rs101.6101.4 100.3%  
Shares outstanding (eoy) m600.001,023.74 58.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x6.92.0 341.9%   
Avg P/E ratio x37.723.7 158.9%  
P/CF ratio (eoy) x26.115.0 173.4%  
Price / Book Value ratio x6.22.8 225.1%  
Dividend payout %6.029.8 20.1%   
Avg Mkt Cap Rs m378,330286,033 132.3%   
No. of employees `0006.113.4 45.7%   
Total wages/salary Rs m11,65324,145 48.3%   
Avg. sales/employee Rs Th8,994.310,632.7 84.6%   
Avg. wages/employee Rs Th1,900.71,801.2 105.5%   
Avg. net profit/employee Rs Th1,635.3898.5 182.0%   
INCOME DATA
Net Sales Rs m55,144142,531 38.7%  
Other income Rs m1,4441,139 126.8%   
Total revenues Rs m56,588143,670 39.4%   
Gross profit Rs m15,88324,198 65.6%  
Depreciation Rs m4,4786,965 64.3%   
Interest Rs m7093,418 20.7%   
Profit before tax Rs m12,14014,954 81.2%   
Minority Interest Rs m9288 3.1%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,1233,198 66.4%   
Profit after tax Rs m10,02612,044 83.2%  
Gross profit margin %28.817.0 169.7%  
Effective tax rate %17.521.4 81.8%   
Net profit margin %18.28.5 215.2%  
BALANCE SHEET DATA
Current assets Rs m48,22887,154 55.3%   
Current liabilities Rs m30,37682,694 36.7%   
Net working cap to sales %32.43.1 1,034.6%  
Current ratio x1.61.1 150.6%  
Inventory Days Days6871 95.6%  
Debtors Days Days8694 91.1%  
Net fixed assets Rs m64,130133,236 48.1%   
Share capital Rs m3,0001,024 293.0%   
"Free" reserves Rs m57,980102,733 56.4%   
Net worth Rs m60,980103,757 58.8%   
Long term debt Rs m15,76632,146 49.0%   
Total assets Rs m121,924236,866 51.5%  
Interest coverage x18.15.4 337.2%   
Debt to equity ratio x0.30.3 83.4%  
Sales to assets ratio x0.50.6 75.2%   
Return on assets %8.86.5 134.9%  
Return on equity %16.411.6 141.6%  
Return on capital %16.813.7 122.0%  
Exports to sales %28.10-   
Imports to sales %18.90-   
Exports (fob) Rs m15,506NA-   
Imports (cif) Rs m10,399NA-   
Fx inflow Rs m15,50652,752 29.4%   
Fx outflow Rs m10,39914,504 71.7%   
Net fx Rs m5,10738,248 13.4%   
CASH FLOW
From Operations Rs m11,54625,054 46.1%  
From Investments Rs m-7,138-10,123 70.5%  
From Financial Activity Rs m-2,417-10,942 22.1%  
Net Cashflow Rs m2,1033,989 52.7%  

Share Holding

Indian Promoters % 40.4 74.8 54.0%  
Foreign collaborators % 20.6 0.0 -  
Indian inst/Mut Fund % 8.4 8.3 101.2%  
FIIs % 10.7 5.9 181.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 19.9 11.0 180.9%  
Shareholders   109,995 44,069 249.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare BIOCON With:   NEULAND LABS  DR. REDDYS LAB  GSK PHARMA  ALEMBIC  PROCTER & GAMBLE HEALTH  

Compare BIOCON With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens Marginally Lower; IndusInd Bank & Tata Steel Top Losers(09:30 am)

Asian stock markets are trading on a mixed note today as disappointing news on US consumer spending dampened sentiment ahead of a closely-watched reading on the health of the Chinese economy.

Related Views on News

BIOCON Announces Quarterly Results (2QFY21); Net Profit Down 23.9% (Quarterly Result Update)

Oct 29, 2020 | Updated on Oct 29, 2020

For the quarter ended September 2020, BIOCON has posted a net profit of Rs 2 bn (down 23.9% YoY). Sales on the other hand came in at Rs 17 bn (up 11.0% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

CADILA HEALTHCARE 2019-20 Annual Report Analysis (Annual Result Update)

Oct 26, 2020 | Updated on Oct 26, 2020

Here's an analysis of the annual report of CADILA HEALTHCARE for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of CADILA HEALTHCARE. Also includes updates on the valuation of CADILA HEALTHCARE.

CADILA HEALTHCARE Announces Quarterly Results (1QFY21); Net Profit Up 49.3% (Quarterly Result Update)

Aug 21, 2020 | Updated on Aug 21, 2020

For the quarter ended June 2020, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (up 49.3% YoY). Sales on the other hand came in at Rs 36 bn (up 4.1% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

BIOCON Announces Quarterly Results (3QFY20); Net Profit Up 1.2% (Quarterly Result Update)

Jan 24, 2020 | Updated on Jan 24, 2020

For the quarter ended December 2019, BIOCON has posted a net profit of Rs 2 bn (up 1.2% YoY). Sales on the other hand came in at Rs 17 bn (up 13.5% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

CADILA HEALTHCARE Announces Quarterly Results (2QFY20); Net Profit Down 79.3% (Quarterly Result Update)

Nov 15, 2019 | Updated on Nov 15, 2019

For the quarter ended September 2019, CADILA HEALTHCARE has posted a net profit of Rs 829 m (down 79.3% YoY). Sales on the other hand came in at Rs 34 bn (up 13.7% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

More Views on News

Most Popular

My Top Stock Recommendation for 2021 and Beyond(Profit Hunter)

Jan 5, 2021

My new guide will show you the huge potential in future proof businesses.

'Essential' Smallcap Stock Recommendations(Profit Hunter)

Jan 8, 2021

The smallcap rally has enough steam left in it. If you haven't joined yet, it is still not too late.

Is Nifty Forming a Top(Fast Profits Daily)

Jan 8, 2021

The charts are telling the bulls to be cautious.

Why Gold Hit Lower Circuit(Fast Profits Daily)

Jan 11, 2021

Were you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

BIOCON SHARE PRICE


Jan 18, 2021 09:44 AM

TRACK BIOCON

COMPARE BIOCON WITH

MARKET STATS